Project Grant R01CA303986
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $649K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60616, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary The University of Wisconsin-Madison received a $630,171 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective August 12, 2025, with a completion date of July 31, 2030. The award supports the development of targeted radiopharmaceutical therapies (RPTs) for triple-negative breast cancer (TNBC), an aggressive breast cancer subtype that lacks expression of estrogen receptor, progesterone...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Illinois a $386,279 Project Grant on July 10, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop innovative immunotherapy screening capabilities. The grant funds the creation of a microfluidic device cassette and associated functional immune assay protocols designed to enable personalized immunotherapy screening directly on core needle biopsies from cancer patients. This...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026 through March 31, 2028. The award supports fundamental research to decipher mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugate therapy, specifically examining the drug sacituzumab govitecan (SG), which is approved for...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University $542,644 on April 1, 2026, through the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate radiation-guided antibody-drug conjugates (ADCs) for non-small cell lung cancer (NSCLC) treatment. The research focuses on leveraging a breakthrough discovery of radiation-inducible antigens, specifically Tax-Interacting Protein 1 (TIP1), which is significantly upregulated on...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Texas at Austin a Project Grant of $668,878 on April 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a novel antibody-drug conjugate (ADC) therapeutic platform targeting CD44 variant 9 (CD44V9) for advanced breast cancer treatment. The research addresses a critical clinical need for improved treatment options for triple-negative and heavily treated hormone...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Methodist Hospital Research Institute a $403,485 Project Grant effective September 1, 2025, through August 31, 2027, under the Cancer Treatment Research program (CFDA 93.395). The research project focuses on the development of novel platinum-based polymers designed to induce robust reactive oxygen species (ROS) production with tumor-specific toxicity, specifically targeting triple negative breast cancer (TNBC). The...
- Federal Grant Award Summary The National Cancer Institute awarded Johns Hopkins University a $591,419 project grant under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026 through April 30, 2031. The award supports the development of low molecular weight theranostics targeting multiple myeloma, a disease characterized by malignant plasma cell expansion in the bone marrow. The research addresses critical gaps in treating therapy-resistant myeloma by developing a...
- Federal Project Grant Award Summary The University of Illinois received a $565,909 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2031. This award funds fundamental research investigating microcalcifications (MCs) in breast cancer through the development and application of engineered mineralized hydrogels that replicate the tumor microenvironment (TME). The research addresses a critical gap...